ANAL

ECOG/ACRIN-EA2182: A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)

The purpose of this study is to compare lower-dose chemoradiation therapy to standard-dose chemoradiation therapy.

Learn more about the ECOG/ACRIN-EA2182 trial or call the Reading Hospital Protocol Office at 484-628-8193.

COLON/RECTAL

Alliance-A021502: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone.

Learn more about the Alliance-A021502 trial or call the Reading Hospital Protocol Office at 484-628-8193.

S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and IrinotecN (cetiri) IN Advanced/Medtastatic Colorectal Cancer (mCRC) with HER-2-Amplification Pottstown Hospital Active Clinical Trials

Learn more about S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

NRG-GI004: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

The purpose of this screening step is to perform a genetic test on the colorectal cancer tumor sample to see if it has a HER-2 gene amplification.

Learn more about the NRG-GI004 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-GI005: Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA).

A purpose of this study is for the study doctors to learn if a ctDNA test done after your surgery for colon cancer is helpful to decide if you should receive chemotherapy.

Learn more about the NRG-GI005 trial or call the Reading Hospital Protocol Office at 484-628-8193.

16-002 / NSABP C-14: CORRECT-MRD II: Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.

The purpose of this research study is to review the ability of the Exact Sciences’ Minimal Residual Disease (Exact MRD) test to detect cancer recurrence after surgery.

Learn more about the 16-002 / NSABP C-14 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Biofilm Epidemiology and Mechanisms of Colon Cancer

Johns Hopkins Primary Investigator: Cynthia Sears, MD

Reading Hospital Primary Investigator: Louis LaLuna, MD

This research is being done to learn more about why people get colon cancer. We are looking to identify specific bacteria in the colon that may be linked to the development of colon cancer, and small biopsies will be taken along with other samples to look for these bacteria. This study is closed to enrollment.

Learn more about the Biofilm trial.

View on Cancer.gov or call the Clinical Trials Office at 484-628-8585 for more information.

ESOPHAGEAL AND GASTRIC

ECOG/ACRIN-EA2183: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma

The purpose of this study is to compare the usual treatment, which consists of chemotherapy alone, to chemotherapy plus the addition of radiation.

Learn more about the ECOG/ACRIN-EA2183 trial or call the Reading Hospital Protocol Office at 484-628-8193.

ESOPHAGEAL AND GASTROESOPHAGEAL JUNCTION

ECOG-ACRIN EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma.

There are two main purposes to this study. One purpose is to compare the usual pre-surgery treatment alone to using nivolumab plus the usual treatment. Another purpose is to compare post-surgery treatment with nivolumab alone to using nivolumab plus ipilimumab.

Learn more about the ECOG-ACRIN EA2174 trial or call the Reading Hospital Protocol Office at 484-628-8193.

PANCREATIC

ECOG-ACRIN EA2186: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT).

The purpose of this study is to determine whether Gemcitabine and Nab-paclitaxel or 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan are more effective treatments for vulnerable patients over the age of 70 with newly diagnosed metastatic pancreatic cancer.

Learn more about the ECOG-ACRIN EA2186 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Alliance-A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.

The purpose of this study is to compare the usual treatment approach (surgery followed by chemotherapy) to using chemotherapy followed by surgery and then more chemotherapy.

Learn more about the Alliance-A021806 trial or call the Reading Hospital Protocol Office at 484-628-8193.